BRPI0410555A - preparação sólida - Google Patents

preparação sólida

Info

Publication number
BRPI0410555A
BRPI0410555A BRPI0410555-9A BRPI0410555A BRPI0410555A BR PI0410555 A BRPI0410555 A BR PI0410555A BR PI0410555 A BRPI0410555 A BR PI0410555A BR PI0410555 A BRPI0410555 A BR PI0410555A
Authority
BR
Brazil
Prior art keywords
solid preparation
hmg
insulin resistance
pharmaceutical preparations
coa reductase
Prior art date
Application number
BRPI0410555-9A
Other languages
English (en)
Inventor
Naoru Hamaguchi
Hiroyoshi Koyma
Masafumi Misaki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0410555A publication Critical patent/BRPI0410555A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"PREPARAçãO SóLIDA". Preparações farmacêuticas sólidas compreendendo um agente de melhora da resistência a insulina e um inibidor de HMG-CoA reductase, em que a estabilidade destes agentes não é deteriorada. Particularmente, preparações farmacêuticas sólidas compreendendo grânulos contendo um agente de melhora da resistência a insulina e grânulos contendo um inibidor de HMG-CoA reductase.
BRPI0410555-9A 2003-06-06 2004-06-03 preparação sólida BRPI0410555A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003162241 2003-06-06
PCT/JP2004/008076 WO2004108161A1 (ja) 2003-06-06 2004-06-03 固形製剤

Publications (1)

Publication Number Publication Date
BRPI0410555A true BRPI0410555A (pt) 2006-06-20

Family

ID=33508660

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410555-9A BRPI0410555A (pt) 2003-06-06 2004-06-03 preparação sólida

Country Status (15)

Country Link
US (1) US20060280794A1 (pt)
EP (1) EP1642593A1 (pt)
KR (1) KR20060016787A (pt)
CN (1) CN1802178A (pt)
AU (1) AU2004244889A1 (pt)
BR (1) BRPI0410555A (pt)
CA (1) CA2528164A1 (pt)
IL (1) IL172206A0 (pt)
MA (1) MA27851A1 (pt)
MX (1) MXPA05013147A (pt)
NO (1) NO20060023L (pt)
RU (1) RU2005137865A (pt)
TW (1) TW200510002A (pt)
WO (1) WO2004108161A1 (pt)
ZA (1) ZA200508932B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318935B2 (en) * 2004-05-21 2008-01-15 Accu-Break Technologies, Inc. Pharmaceutical tablets with active and inactive segments
US7329418B2 (en) * 2004-05-21 2008-02-12 Accu Break Technologies, Inc. Pharmaceutical tablets having height greater than width
US7780985B2 (en) * 2005-07-12 2010-08-24 Accu-Break Technologies, Inc. Tablets having a printed separation mark to guide breaking
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
US7838031B2 (en) 2004-05-21 2010-11-23 Lawrence Solomon Method of administering a partial dose using a segmented pharmaceutical tablet
US7713547B2 (en) 2004-05-21 2010-05-11 Accu-Break Pharmaceuticals, Inc. Method of administering a partial dose of a segmented pharmaceutical tablet
CA2565029C (en) * 2004-05-21 2013-09-03 Lawrence Solomon Immediate release pharmaceutical tablets with height greater than width
KR100714616B1 (ko) * 2005-06-23 2007-05-07 삼성전기주식회사 지수 함수 발생기 및 이를 이용한 가변 이득 증폭기
CN1331476C (zh) * 2005-07-05 2007-08-15 凌沛学 一种辅酶a舌下含片及其制备方法
WO2007058660A1 (en) * 2005-11-18 2007-05-24 Accu-Break Technologies, Inc. Segmented pharmaceutical dosage forms
AU2006328328B2 (en) * 2005-12-22 2012-08-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
US20070237815A1 (en) * 2006-04-06 2007-10-11 Lawrence Solomon Dosage forms and methods comprising amlodipine and chlorthalidone
JP2010500374A (ja) * 2006-08-08 2010-01-07 エーシーシーユー−ブレイク テクノロジーズ，インク． 複数の活性セグメントを含む薬剤の錠剤
EP2083801A1 (en) * 2006-11-30 2009-08-05 Accu-Break Technologies, Inc. Divisible osmotic dosage forms and methods of use
CA2672157C (en) * 2006-12-07 2016-07-26 Daiichi Sankyo Company, Limited Method for producing solid preparation
WO2008091870A2 (en) * 2007-01-24 2008-07-31 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions comprising atorvastatin and nicotinic acid
TW200901959A (en) * 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
CN101632672B (zh) * 2008-07-24 2011-01-12 鲁南制药集团股份有限公司 一种用于治疗高血压的复方药物组合物
CA2782776A1 (en) 2008-12-04 2010-06-10 Ikfe Gmbh Biomarkers for atherosclerosis
US20110118134A1 (en) 2008-12-11 2011-05-19 Ikfe Gmbh Biomarkers for insulin sensitizer drug response
US20100209350A1 (en) 2008-12-30 2010-08-19 Andreas Pfuetzner Biomarkers for Adipose Tissue Activity
EP2382475A2 (en) 2009-01-07 2011-11-02 IKFE GmbH Biomarkers for appetite regulation
TR201005325A2 (tr) * 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
CN102028671A (zh) * 2010-12-27 2011-04-27 山东淄博新达制药有限公司 盐酸吡格列酮胶囊及其制备方法
HRP20151321T1 (hr) * 2011-01-20 2016-01-29 Bionevia Pharmaceuticals Inc. Epalrestat ili njegov derivat u oblicima s prilagođenim otpuštanjem te postupci uporabe istih
US9339543B2 (en) 2011-10-12 2016-05-17 Merck Sharp & Dohme Corp. Pharmaceutical compositions that inhibit disproportionation
AU2012326976B2 (en) 2011-10-21 2017-08-17 Takeda Pharmaceutical Company Limited Sustained-release preparation
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
WO2017062954A1 (en) 2015-10-09 2017-04-13 Binutra Incorporated Capsule with internal diaphragm for improved bioavailability
CN108421045B (zh) * 2018-04-02 2021-09-24 北京海晶生物医药科技有限公司 一种阿托伐他汀钙组合物、制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4294819A (en) * 1980-08-18 1981-10-13 Bristol-Myers Company Alkaline analgesic capsule
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
JPH05229936A (ja) * 1992-02-19 1993-09-07 Lion Corp 内服用顆粒製剤
DK0724885T3 (da) * 1993-10-21 2002-05-21 Hisamitsu Pharmaceutical Co Pernasal sammensætning og pernasalt præparat indeholdende dette
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
JP3651816B2 (ja) * 1995-07-03 2005-05-25 三共株式会社 動脈硬化症予防および治療剤
SE9804314D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New pharmaceutical formulation
JP2001294537A (ja) * 2000-02-10 2001-10-23 Takeda Chem Ind Ltd 併用医薬
WO2003105809A1 (en) * 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them

Also Published As

Publication number Publication date
RU2005137865A (ru) 2006-06-10
CA2528164A1 (en) 2004-12-16
WO2004108161A1 (ja) 2004-12-16
AU2004244889A1 (en) 2004-12-16
KR20060016787A (ko) 2006-02-22
NO20060023L (no) 2006-03-06
MA27851A1 (fr) 2006-04-03
EP1642593A1 (en) 2006-04-05
TW200510002A (en) 2005-03-16
IL172206A0 (en) 2006-04-10
CN1802178A (zh) 2006-07-12
ZA200508932B (en) 2007-03-28
US20060280794A1 (en) 2006-12-14
MXPA05013147A (es) 2006-03-17

Similar Documents

Publication Publication Date Title
MXPA05013147A (es) Preparacion solida.
DE69925133D1 (de) Pyrrolobenzodiazepine
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
AU2002246411A1 (en) Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same
NO20022998D0 (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
BR0317715A (pt) Composições e processos de uso de collajolie
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
MXPA03007140A (es) Derivados de carbolina.
EE200100405A (et) 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks
DE50214263D1 (de) Emollients und kosmetische zusammensetzungen enthaltend 2-methyl-1,3-propandioldiester
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
WO2005065657A3 (en) Solid compositions of low-solubility drugs and poloxamers
ATE320256T1 (de) Succinate des 5,8,14-triazatetracyclo(10.3.1.0 2, 11 .0 4,9 )-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
BRPI0415053B8 (pt) inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
BRPI0414979A (pt) preparação sólida
ATE409040T1 (de) Kombination enthaltend substanzen mit npy- rezeptor affinität und substanzen mit 5-ht6- rezeptor affinität
AR043327A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
ATE264839T1 (de) Amino-thiolester-verbindungen, diese enthaltende pharmazeutische und kosmetische zusammensetzungen und ihre anwendungen
HRPK20030766B3 (en) Combination of a taxane and cyclin-dependent kinase inhibitor
SE0102910D0 (sv) New use
EP1510511A4 (en) GINGEROL ANALOGS AND THEIR USE
GEP20084546B (en) Novel association consisting of an anti-atherothrombotic agent and of platelet antiaggregating agent

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]